Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

Overview

About this study

The purpose of this study is to learn whether it is better to receive the drug Metformin with standard of care for lung cancer or just standard of care.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Suspected or biopsy proven Stage IA, IB-IIIA NSCLC-squamous. Diagnosis must be proven at the time of surgery
  • Coincident bronchial dysplasia and/or carcinoma in situ from at least 1 non-resected location
  • Medically fit for surgical resection (based on surgeon assessment)
  • Current or prior smoker
  • Age > 18 years old
  • Both Male and Female
  • Willing and able to consent to study, undergo study interventions, and take study drug
  • ECOG performance status 0, 1, 2
  • Must start Metformin within 90 days of surgery

Exclusion Criteria

  • Currently taking metformin or other diabetic drugs
  • Current or previous congestive heart failure, renal failure or liver failure
  • Existing cancers or prior cancers in the last 5 years and received neo-adjuvant platinum based chemotherapy or targeted therapy, and is receiving adjuvant platinum based chemotherapy or targeted therapy after surgical resection
  • Creatinine in Women of 1.4 or greater and Creatinine in Men of 1.5 or greater

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Dennis Wigle, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions